Fig. 6: NANOG, TRPV1, and pEGFR expression in human cervical cancer patients. | Nature Communications

Fig. 6: NANOG, TRPV1, and pEGFR expression in human cervical cancer patients.

From: TRPV1 inhibition overcomes cisplatin resistance by blocking autophagy-mediated hyperactivation of EGFR signaling pathway

Fig. 6

a Representative image of immunohistochemical staining in chemoradiosensitive and chemoradioresistant patient specimens. The boxed regions are displayed at high magnification in the inset. Scale bar, 100 µm. b Box plot depiction of NANOG, TRPV1, and pEGFR protein expression in chemoradiosensitive (n = 43) and chemoradioresistant (n = 21) cervical cancer patients. c Combinations of NANOG, TRPV1, and pEGFR expression were compared between chemoradiosensitive and chemoradioresistant cervical cancer cases. d Kaplan–Meier plots of overall survival according to combinations of NANOG, TRPV1, and pEGFR expression. In the box plots, the top and bottom edges of boxes indicate the first and third quartiles, respectively; the center lines indicate the medians; and the ends of whiskers indicate the maximum and minimum values, respectively. The p values by two-tailed Student’s t test (b), Mann–Whitney U test (c), or Gehan–Breslow–Wilcoxon test (d) are indicated. The data represent the mean ± SD. Source data are provided as a Source Data file. (NS, not significant).

Back to article page